Find Information About:

Drugs & Supplements

Get information and reviews on prescription drugs, over-the-counter medications, vitamins, and supplements. Search by name or medical condition.

Pill Identifier

Pill Identifier

Having trouble identifying your pills?

Enter the shape, color, or imprint of your prescription or OTC drug. Our pill identification tool will display pictures that you can compare to your pill.

Get Started

My Medicine

Save your medicine, check interactions, sign up for FDA alerts, create family profiles and more.

Get Started

WebMD Health Experts and Community

Talk to health experts and other people like you in WebMD's Communities. It's a safe forum where you can create or participate in support groups and discussions about health topics that interest you.

  • Second Opinion

    Second Opinion

    Read expert perspectives on popular health topics.

  • Community


    Connect with people like you, and get expert guidance on living a healthy life.

Got a health question? Get answers provided by leading organizations, doctors, and experts.

Get Answers

Sign up to receive WebMD's award-winning content delivered to your inbox.

Sign Up

Font Size

New C. diff Drug OK'd by FDA Panel

New Antibiotic Effective, May Lower Risk of C. diff Recurrence
WebMD Health News
Reviewed by Laura J. Martin, MD

April 5, 2011 – The FDA should approve Optimer's fidaxomicin for the treatment of the C. diff superbug, an expert advisory panel today unanimously agreed.

C. diff (Clostridium difficile) infects as many as 3 million Americans every year, making it the top bacterial cause of severe diarrhea in the nation. Only one other drug, vancomycin, is FDA approved for treating the difficult-to-eradicate bug.

Although metronidazole is often used as an "off-label" C. diff treatment, it often fails. "Off-label" refers to the practice of prescribing drugs for a purpose not specifically approved by the FDA. Fidaxomicin is designed to attack only C. diff, and may have less harmful effects on helpful gut bacteria.

While the panel voted 13-0 in favor of approving fidaxomicin, it split in a 6-6 vote, with one abstention, over whether the FDA should let Optimer claim that the drug prevents C. diff recurrence.

Recurrence is one of the worst things about C. diff. Even after successful treatment, up to 20% to 30% of patients see their C. diff infections come back. Many of these patients have recurrent attacks over the course of months or even years.

Recurrence usually happens within 60 days of the initial treatment. Optimer's clinical trials showed that fidaxomicin cut recurrences over 31 days.

The panel vote -- and the desperate need for new C. diff treatments -- makes rapid FDA approval appear likely. But the FDA and Optimer will have to wrangle about the exact claims that can be made about how well the drug prevents C. diff recurrence.

Today on WebMD

man holding his stomach
Get the facts on common problems.
blueberries in a palm
Best and worst foods.
woman shopping
Learn what foods to avoid.
fresh and dried plums
Will it help constipation?
top foods for probiotics
couple eating at cafe
sick child
Woman blowing bubble gum

Send yourself a link to download the app.

Loading ...

Please wait...

This feature is temporarily unavailable. Please try again later.


Now check your email account on your mobile phone to download your new app.

Woman with crohns in pain
Woman with stomach pain
diet for diverticulitis
what causes diarrhea